As part of an international clinical trial, Jacksonville-based Mayo Clinic in Florida has become the first U.S. site to target metastatic breast cancer with the radiopharmaceutical actinium-225.
The trial drug, which contains actinium-225, was developed to treat a subtype of gastroenteropancreatic neuroendocrine tumors. It is designed to “stick” to cancer cells as it delivers radiation without harming healthy cells, according to an Aug. 1 news release from the health system.
Mayo Clinic’s academic centers in Rochester, Minn., Phoenix and Jacksonville are participating in the trial, alongside 20 other sites across the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
